Recent Advances in Combating Bacterial Infections by Using Hybrid Nano-Systems

Patel, Unnati; Hunt, Emily C.

doi:10.3390/jnt4030019

Cited by 5 publications

(2 citation statements)

References 201 publications

(255 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Porous silicon nanoparticles, for instance, have been designed to transport novel antimicrobial peptides fused with synthetic bacterial toxins. These engineered nanoparticles have demonstrated the ability to enhance survival rates and bacterial clearance in mouse models of P. aeruginosa lung infections (Patel and Hunt, 2023). Moreover, nanoparticles can serve as carriers for antibiotics, significantly augmenting their efficacy.…”

Section: Nanoparticlesmentioning

confidence: 99%

Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Elfadadny,

Ragab,

AlHarbi

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

Pseudomonas aeruginosa, a Gram-negative bacterium, is recognized for its adaptability and opportunistic nature. It poses a substantial challenge in clinical settings due to its complicated antibiotic resistance mechanisms, biofilm formation, and capacity for persistent infections in both animal and human hosts. Recent studies revealed a potential zoonotic transmission of P. aeruginosa between animals, the environment, and human populations which highlights awareness of this microbe. Implementation of the One Health approach, which underscores the connection between human, animal, and environmental health, we aim to offer a comprehensive perspective on the current landscape of P. aeruginosa management. This review presents innovative strategies designed to counteract P. aeruginosa infections. Traditional antibiotics, while effective in many cases, are increasingly compromised by the development of multidrug-resistant strains. Non-antibiotic avenues, such as quorum sensing inhibition, phage therapy, and nanoparticle-based treatments, are emerging as promising alternatives. However, their clinical application encounters obstacles like cost, side effects, and safety concerns. Effectively addressing P. aeruginosa infections necessitates persistent research efforts, advancements in clinical development, and a comprehension of host-pathogen interactions to deal with this resilient pathogen.

show abstract

Section: Nanoparticlesmentioning

confidence: 99%

Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Elfadadny,

Ragab,

AlHarbi

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“… 5 – 7 Nanoparticles can be designed as drug-delivery systems that increase the solubility and the circulation time of the chemotherapeutic drugs, and additionally, nanoparticle therapies can incorporate ligands that allow for precise targeting of the cancer cells. 6 , 8 …”

Section: Introductionmentioning

confidence: 99%

Fabrication of a Dual-Targeted Liposome-Coated Mesoporous Silica Core–Shell Nanoassembly for Targeted Cancer Therapy

Rathnayake,

Patel,

Hunt

et al. 2023

ACS Omega

View full text Add to dashboard Cite

Nanoparticles have been suggested as drug-delivery systems for chemotherapeutic drugs to allow for controlled drug release profiles and selectivity to target cancer cells. In addition, nanoparticles can be used for the in situ generation and amplification of reactive oxygen species (ROS), which have been shown to be a promising strategy for cancer treatment. Thus, a targeted nanoscale drug-delivery platform could be used to synergistically improve cancer treatment by the action of chemotherapeutic drugs and ROS generation. Herein, we propose a promising chemotherapy strategy where the drug-loaded nanoparticles generate high doses of ROS together with the loaded ROS-generating chemotherapeutic drugs, which can damage the mitochondria and activate cell death, potentiating the therapeutic outcome in cancer therapy. In the present study, we have developed a dual-targeted drug-delivery nanoassembly consisting of a mesoporous silica core loaded with the chemotherapeutic, ROS-generating drug, paclitaxel (Px), and coated with a liposome layer for controlled drug release. Two different lung cancer-targeting ligands, folic acid and peptide GE11, were used to target the overexpressed nonsmall lung cancer receptors to create the final nanoassembly (MSN@Px) L-GF. Upon endocytosis by the cancer cells, the liposome layer was degraded by the intracellular lipases, and the drug was rapidly released at a rate of 65% within the first 20 h. In vitro studies confirmed that this nanoassembly was 8-fold more effective in cancer therapy compared to the free drug Px.

show abstract

Antibacterial activity of engineered nanoparticles against fish pathogens

Dube

2024

Aquaculture Reports

View full text Add to dashboard Cite

Recent Advances in Combating Bacterial Infections by Using Hybrid Nano-Systems

Cited by 5 publications

References 201 publications

Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Fabrication of a Dual-Targeted Liposome-Coated Mesoporous Silica Core–Shell Nanoassembly for Targeted Cancer Therapy

Antibacterial activity of engineered nanoparticles against fish pathogens

Contact Info

Product

Resources

About